MSMantabya Kumar Singh

Mantabya Kumar Singh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mantabya Kumar Singh has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Management of type 2 diabetes mellitus using Yoga: Implications for immunological and autonomic dysfunction

    by Rukadikar C.A., Geetha M, Dixit A.M., Renuka K, Vinoth R, Nishad S, Rukadikar A.R., Singh M.K.

    Type 2 diabetes mellitus (T2DM) is characterized by chronic hyperglycaemia, insulin resistance and β-cell dysfunction, leading to systemic inflammation and autonomic nervous system impairment. Diabetic autonomic neuropathy and cardiac autonomic neuropathy significantly increase risks of cardiovascular morbidity and mortality. Metabolic disturbances such as oxidative stress, polyol pathway activation and AGEs contribute to progressive neuronal and microvascular injury. Emerging evidence shows that yoga improves glycaemic control, autonomic balance and neuro-endocrine functioning in individuals with T2DM. Thus, we show that yoga as a complementary therapeutic approach to mitigate neuro-immunological dysregulation and enhance cardiovascular health in T2DM.

  • Open Access

    Humoral Immune Response of SARS-CoV-2 Infection and Anti-SARS-CoV-2 Vaccination in Renal Transplant Recipients

    by Narayan Prasad, Brijesh Yadav, Mantabya Singh, Sonam Gautam, Dharmendra Bhadauria, Manas Patel, Ravi Kushwaha, Deependra Yadav, Ankita Singh, Monika Yachha, et al.

    Vaccination-induced SARS-CoV-2 neutralizing antibodies are required for herd immunity. Vaccine availability and poor vaccine response in renal transplant recipients (RTRs) remain a concern. There is no report on the efficacy of Covaxin and Covishield vaccines in RTRs. We recruited 222 live donors RTRs and analyzed the serum titer of anti-SARS-CoV-2 spike protein antibody by chemiluminescent magnetic microparticle immunoassay. Patients were categorized into three groups: group1 with SARS-CoV-2 infection and no vaccination (n = 161); group 2 with only vaccination and no SARS-CoV-2 infection (n = 41); and group 3 with both vaccination and SARS-CoV-2 infection (n = 20). Overall seroconversion rate was 193/222 (86.9%) with a median titer 1095.20 AU/mL. The median IgG titer value in group 1 was 647.0 AU/mL; group 2 was 1409.0 AU/mL; and group 3 was 1831.30 AU/mL. Covaxin associated seroconversion was observed in 16/19 (84.21%), with a median titer of 1373.90 AU/mL compared to that of Covishield 32/42 (76.19%), whose median titer was 1831.10 AU/mL. The seroconversion rate due to SARS-CoV-2 infection was 145 (90.06%), it was lowest with the vaccination-only group (70.7%), and with both vaccination and SARS-CoV-2 infection group it was highest (95%). In RTRs, SARS-CoV-2 infection and both Covaxin and Covishield vaccination effectively induce a humoral immune response against the SARS-CoV-2 spike protein; however, seroconversion rate was lower and the antibody titer was higher with vaccine than infection.


  • The prevalence and clinical characteristics of anti-HMGCR (anti-3-hydroxy-3-methyl-glutaryl-coenzyme A reductase) antibodies in idiopathic inflammatory myopathy: an analysis from the MyoCite registry

    by Latika Gupta, Arvind Nune, R. Naveen, Ritu Verma, Pallavi Prasad, Rajat Kharbanda, Upendra Rathore, Mohit Kumar Rai, Mantabya Kumar Singh, Anamika Kumari Anuja, et al.

    This study aimed to determine the prevalence and clinical characteristics of anti-HMGCR antibodies in idiopathic inflammatory myositis (IIM) at a tertiary care centre in northern India. Data (adult and children) were retrieved from the MyoCite dataset, identifying patients with polymyositis, dermatomyositis, and antibody-negative IIM whilst fulfilling the ACR/EULAR criteria. SLE, sarcoidosis, and systemic sclerosis were included for comparison as disease controls. The baseline clinical profile, laboratory tests, and muscle biopsies were retrieved and analysed. Descriptive statistics and non-parametric statistics were used for comparison. Among 128 IIM (112 adults, 16 children, M:F 1:2.8) of age 37 (24–47) years and 6 (3–17) months disease duration, 4 (3.6%) young adults tested positive for anti-HMGCR antibodies. All children and disease control tested negative for the antibody. Anti-HMGCR + IIM exhibited higher muscle enzymes [AST (367 vs 104 IU/L, p = 0.045), ALT (502 vs 78 IU/L, p = 0.004), and CPK (12,242 vs 699 IU/L, p = 0.001] except lactate dehydrogenase with less frequent systemic features such as fatigue than antibody-negative IIM. One young girl presented with a Limb–girdle muscular dystrophy (LGMD) with chronic pattern. None of the patients exhibited rashes, statin exposure, or cancer, though one had anti-Ro52 and mild disease. Our observations depict a younger population while affirming previous literature, including NM-like presentation, and chronic LGMD-like pattern of weakness in one case. Although a small number of children were included, ours is one of the few paediatric studies that evaluated HMGCR antibodies thus far. Further investigations in a larger Indian cohort are warranted to substantiate our findings.


  • Open Access

    NMR‐based serum and muscle metabolomics for diagnosis and activity assessment in idiopathic inflammatory myopathies

    by Anupam Guleria, Umesh Kumar, Dinesh Kumar, Naveen R, Anamika Kumari Anuja, Mantabya Kumar Singh, Pulak Sharma, Vikas Agarwal, Ramnath Misra, Latika Gupta

    Objectives: Differentiating smoldering disease activity from weakness due to fatty replacement of atrophied muscle can often be a challenge in the idiopathic inflammatory myositis (IIM). We aimed to identify the metabolic disturbances associated with IIM and if these changes can aid in the assessment of disease activity.Methods: Metabolic profiles of sera (N = 99) and muscle (N = 21) from patients with IIM (ACR‐EULAR criteria) were compared with healthy control (HC) samples (N = 75 for serum and N = 12 for muscle tissues) employing 800 MHz NMR (Nuclear Magnetic Resonance) spectroscopy. Metabolic disparity between IIM and HC was established based on Partial Least Squares Discriminant Analysis (PLS‐DA) and the discriminatory metabolites were identified based on variable importance in projection (VIP) statistics (P‐value < .05, corrected for false discovery rate (FDR)).Results: Serum metabolomics profiles were distinctive in IIM as compared to HC, with a visible shift to anaerobic metabolism (increased lactate, low glucose), oxidative defect (high Phenylalanine/tyrosine), decreased muscle mass (low serum creatinine), increased muscle catabolism (increased branched‐chain amino acids), and dyslipidemia (higher lipids, higher very low‐density lipoprotein [VLDL]/low‐density lipoprotein [LDL] ratio, lower polyunsaturated fatty acid [PUFA]). The sera of active IIM patients were characterized by anaerobic metabolism (low glucose), loss of muscle mass (low creatinine, amino acids), and oxidative defect (high Phenylalanine/tyrosine). Three metabolites (isopropanol, succinate, and glycine) were distinctive in muscle tissue metabolomics. NMR‐based serum metabolic disparity was lacking between different clinical subsets of IIM.Conclusion: Serum and muscle tissue metabolomics have the potential to distinguish (a) IIM from HC and (b) active IIM from inactive IIM irrespective of disease subtype.